

AMENDMENTS TO THE CLAIMS

Please amend the following claims as indicated.

1. (Deleted)
2. (Deleted)
3. (Deleted)
4. (Currently Amended) (Currently Amended) A method of using of the G protein-coupled protein p2y9 comprising amino acid sequence substantially represented by SEQ ID NO:1 as a lysophosphatidic acid (LPA) receptor.
5. (Currently Amended) The ~~use~~ method of using according to claim 4, wherein LPA is 1-acyl-LPA.
6. (Currently Amended) The ~~use~~ method of using according to ~~claim~~ any one of claims 4 or 5, wherein p2y9 has ~~an~~ the amino acids sequence of SEQ ID NO:1 in the sequence listing.
7. (Previously Presented) A method for screening a compound which regulate physiological activities stimulated or inhibited by lysophosphatidic acid (LPA) by using lysophosphatidic acid (LPA) receptor comprising G protein-coupled protein p2y9.
8. (Original) The method according to claim 7, wherein the method is to screen the antagonist in use for carcinoma cell invasion.
9. (New) A method of using of the G protein-coupled protein p2y9 as a lysophosphatidic acid or the mutant which maintains the same function as a lysophosphatidic acid.